Use of tocilizumab in the combination treatment of a COVID-19 patient with concomitant rheumatoid arthritis (a case report)

Authors

DOI:

https://doi.org/10.14739/2310-1210.2021.5.232322

Keywords:

COVID-19, rheumatoid arthritis, cytokine release syndrome, tocilizumab

Abstract

The aim is to familiarize practitioners with the clinical case of tocilizumab use in the combination treatment of the coronavirus disease (COVID-19) patient with concomitant rheumatoid arthritis.

Materials and methods. The clinical case shows our own follow-up of COVID-19 clinical course in the patient with concomitant rheumatoid arthritis during combination treatment with the use of a recombinant humanized anti-interleukin-6 receptor monoclonal antibody tocilizumab.

Results. The patient with a severe COVID-19 course, whose examination and treatment results are given in the article, was comorbid for rheumatoid arthritis. The cytokine storm development at the hospital stage was confirmed by an increase in markers of systemic inflammation: C-reactive protein, D-dimer, fibrinogen, an almost 50-fold increase in serum interleukin-6 level, as well as absolute and relative lymphocytopenia. Despite the anti-inflammatory therapy administered with systemic corticosteroids, the patient’s condition progressively worsened. After assessing the indications and contraindications, it was decided to use the interleukin-6 receptor inhibitor tocilizumab, followed by rapid clinical, laboratory and X-ray positive response to the treatment. The understanding of tocilizumab use in patients with COVID-19 at the current stage was formed based on the comparative analysis of our own clinical case data and the results of relevant clinical trials, world recommendations and guidelines.

Conclusions. The use of recombinant humanized anti-interleukin-6 receptor monoclonal antibody tocilizumab in the combination treatment of severe COVID-19 with concomitant rheumatoid arthritis is pathogenetically based and decreases the main clinical and laboratory signs of cytokine storm, respiratory failure, improves chest x-ray findings and reduces the length of hospital stay. Further large randomized placebo-controlled trials including the population of patients with various comorbid conditions are needed to clarify conclusively the place and role of anti-cytokine drugs in the treatment of COVID-19 patients.

Author Biographies

V. A. Vizir, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Internal Diseases 2

A. S. Sadomov, Zaporizhzhia State Medical University, Ukraine

MD, PhD, Associate Professor of the Department of Internal Diseases 2

O. V. Demidenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD, Associate Professor, Head of the Department of Internal Diseases 2

References

Wang, Q., Liu, J., Shao, R., Han, X., Su, C., & Lu, W. (2021). Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatology International, 41(5), 851-861. https://doi.org/10.1007/s00296-021-04803-9

RECOVERY Collaborative Group, Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., … Landray, M. J. (2021). Dexamethasone in Hospitalized Patients with Covid-19. The New England Journal of Medicine, 384(8), 693-704. https://doi.org/10.1056/NEJMoa2021436

Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., Cameron, M. L., Garcia-Diaz, J., Chávez, V., Mekebeb-Reuter, M., Lima de Menezes, F., Shah, R., González-Lara, M. F., Assman, B., Freedman, J., & Mohan, S. V. (2021). Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. The New England Journal of Medicine, 384(1), 20-30. https://doi.org/10.1056/NEJMoa2030340

RECOVERY Collaborative Group. (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397(10285), 1637-1645. https://doi.org/10.1016/S0140-6736(21)00676-0

Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S., Boffini, N., Da Prat, V., Di Terlizzi, G., Lanzillotta, M., Rovere Querini, P., Ruggeri, A., Landoni, G., Tresoldi, M., Ciceri, F., Zangrillo, A., De Cobelli, F., Dagna, L., SARI-RAF Study Group, & SARI-RAF Study Group members. (2020). Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases, 79(10), 1277-1285. https://doi.org/10.1136/annrheumdis-2020-218122

Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., Savic, S., Youngstein, T., Del Sorbo, L., Cubillo Gracian, A., De La Zerda, D. J., Ustianowski, A., Bao, M., Dimonaco, S., Graham, E., Matharu, B., … Malhotra, A. (2021). Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England Journal of Medicine, 384(16), 1503-1516. https://doi.org/10.1056/NEJMoa2028700

Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., Cardiel, M. H., … van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 79(6), 685-699. https://doi.org/10.1136/annrheumdis-2019-216655

Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C., Edwards, K. M., Gandhi, R., Gallagher, J., Muller, W. J., O'Horo, J. C., Shoham, S., Murad, M. H., Mustafa, R. A., Sultan, S., & Falck-Ytter, Y. (2020, November 4). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

National Institute for Health and Care Excellence. (2021, March 23). COVID-19 rapid guideline: managing COVID-19. NICE. https://www.nice.org.uk/guidance/ng191

National Institutes of Health. (n.d.). COVID-19 Treatment Guidelines. NIH. https://www.covid19treatmentguidelines.nih.gov/

D'Silva, K. M., & Wallace, Z. S. (2021). COVID-19 and rheumatoid arthritis. Current Opinion in Rheumatology, 33(3), 255-261. https://doi.org/10.1097/BOR.0000000000000786

Ministry of Health of Ukraine. (2020, December 31). Pro vnesennia zmin do protokolu "Nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)" [On Amendments to the Protocol "Provision of Medical Care for the Treatment of Coronavirus Disease (COVID-19)" (No. 3094)]. https://zakon.rada.gov.ua/rada/show/v3094282-20#Text

Landewé, R. B., Machado, P. M., Kroon, F., Bijlsma, H. W., Burmester, G. R., Carmona, L., Combe, B., Galli, M., Gossec, L., Iagnocco, A., Isaacs, J. D., Mariette, X., McInnes, I., Mueller-Ladner, U., Openshaw, P., Smolen, J. S., Stamm, T. A., Wiek, D., & Schulze-Koops, H. (2020). EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases, 79(7), 851-858. https://doi.org/10.1136/annrheumdis-2020-217877

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation, 130(5), 2620-2629. https://doi.org/10.1172/JCI137244

Gupta, S., Wang, W., Hayek, S. S., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., Reiser, J., Bansal, A., Srivastava, A., Zhou, Y., Finkel, D., Green, A., Mallappallil, M., Faugno, A. J., Zhang, J., Velez, J., … STOP-COVID Investigators. (2021). Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Internal Medicine, 181(1), 41-51. https://doi.org/10.1001/jamainternmed.2020.6252

Malgie, J., Schoones, J. W., & Pijls, B. G. (2021). Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies. Clinical Infectious Diseases, 72(11), e742-e749. https://doi.org/10.1093/cid/ciaa1445

Hoffmann-La Roche. (2020, March 25). A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04320615

Hoffmann-La Roche. (2020, June 1). A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04409262

Hoffmann-La Roche. (2020, May 1). A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04372186

Ministry of Health of Ukraine. (2021, May 13). Pro vnesennia zmin do protokolu "Nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)" [On Amendments to the Protocol "Provision of Medical Care for the Treatment of Coronavirus Disease (COVID-19)" (No. 930)]. https://zakon.rada.gov.ua/rada/show/v0930282-21#Text

Fix, O. K., Hameed, B., Fontana, R. J., Kwok, R. M., McGuire, B. M., Mulligan, D. C., Pratt, D. S., Russo, M. W., Schilsky, M. L., Verna, E. C., Loomba, R., Cohen, D. E., Bezerra, J. A., Reddy, K. R., & Chung, R. T. (2020). Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology, 72(1), 287-304. https://doi.org/10.1002/hep.31281

Del Zompo, F., De Siena, M., Ianiro, G., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2020). Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. European Review for Medical and Pharmacological Sciences, 24(24), 13072-13088. https://doi.org/10.26355/eurrev_202012_24215

Aktemra (Actemra®). (n.d.). Kompendyum OnLine. https://compendium.com.ua/dec/264817/

Downloads

Published

2021-09-01

How to Cite

1.
Vizir VA, Sadomov AS, Demidenko OV. Use of tocilizumab in the combination treatment of a COVID-19 patient with concomitant rheumatoid arthritis (a case report). Zaporozhye medical journal [Internet]. 2021Sep.1 [cited 2024Apr.19];23(5):739-48. Available from: http://zmj.zsmu.edu.ua/article/view/232322

Issue

Vol. 23 No. 5 (2021)

Section

Case Reports

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)